Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 3245-3267

  Khalin, Igor ^a   Alyautdin, Renad ^b   Kocherga, Ganna ^c   Bakar, Muhamad Abu ^a  

^a NATIONAL DEFENCE UNIVERSITY OF MALAYSIA   (Malaysia)

^b Scientific Centre for Expert Evaluation of Medicinal Products   (Russian Federation)

^c Ophthalmic Microsurgery Department International Medical Center Oftalmika   (Ukraine)

Author keywords

Brain derived neurotrophic factor; Inner ear; Nanoparticles; Neurodegeneration; Posterior eye segment; Targeted drug delivery

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CHONDROITIN ABC LYASE; CILIARY NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR; FORSKOLIN; GELFOAM; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYALURONIC ACID; LONG ACTING DRUG; N(G) NITROARGININE METHYL ESTER; NANOPARTICLE; NEUROTROPHIN RECEPTOR P75; NEURTURIN; PARVOVIRUS VECTOR; POLYGLACTIN; SORTILIN; VIRUS VECTOR;

ARTICLE; BLINDNESS; BLOOD RETINA BARRIER; CELL SURVIVAL; CELL THERAPY; COCHLEA; COCHLEA FENESTRA; ELECTROPORATION; ELECTROSTIMULATION; EVOKED BRAIN STEM AUDITORY RESPONSE; HAIR CELL; HEARING IMPAIRMENT; HEMATOPOIETIC STEM CELL; HERPES SIMPLEX VIRUS; HUMAN; HYDROGEL; INNER EAR; MESENCHYMAL STEM CELL; MUELLER CELL; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OPTIC NERVE INJURY; OPTIMAL DRUG DOSE; OSMOTIC MINIPUMP; PIGMENT CELL; POSTERIOR EYE SEGMENT; RETINA GANGLION CELL; SCHWANN CELL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPIRAL GANGLION CELL; SUSTAINED DRUG RELEASE; VIRAL GENE THERAPY; ANIMAL; BLOOD BRAIN BARRIER; CELL LINE; DEAFNESS; DRUG DELIVERY SYSTEM; METABOLISM; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; BLINDNESS; BLOOD-BRAIN BARRIER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE; DEAFNESS; DRUG DELIVERY SYSTEMS; HUMANS; MICE;

EID: 84929429281     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S77480     Document Type: Article

References (223)

1. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155–175.
2. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med. 2009;15(3):331–337.
3. Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neu-rotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. J Neurosci. 1995;15(12):7810–7820.
4. Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington’s disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther. 1999;10(18):2987–2997.
5. Li W, Pozzo-Miller L. BDNF deregulation in Rett syndrome. Neurop-harmacology. 2014;76(Pt C):737–746.
6. Schabitz WR, Schwab S, Spranger M, Hacke W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1997;17(5):500–506.
7. Blaha GR, Raghupathi R, Saatman KE, McIntosh TK. Brain-derived neurotrophic factor administration after traumatic brain injury in the rat does not protect against behavioral or histological deficits. Neurosci-ence. 2000;99(3):483–493.
8. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005;1037(1–2):204–208.
9. Otis JM, Fitzgerald MK, Mueller D. Infralimbic BDNF/TrkB enhancement of GluN2B currents facilitates extinction of a cocaine-conditioned place preference. J Neurosci. 2014;34(17):6057–6064.
10. Koeva YA, Sivkov ST, Akabaliev VH, et al. Brain-derived neurotrophic factor and its serum levels in schizophrenic patients. Folia Med. 2014; 56(1):20–23.
11. Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4(1):22–26.
12. Makar TK, Bever CT, Singh IS, et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol. 2009;210(1–2): 40–51.
13. Chen Y, Liu L. Modern methods for delivery of drugs across the blood– brain barrier. Adv Drug Deliv Rev. 2012;64(7):640–665.
14. Pardridge WM. Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–1972.
15. Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood–brain barrier. Int J Nanomedicine. 2014;9:795–811.
16. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58(11):1136–1163.
17. Juhn SK, Rybak LP, Fowlks WL. Transport characteristics of the blood–perilymph barrier. Am J Otolaryngol. 1982;3(6):392–396.
18. Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237(4819):1154–1162.
19. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1(5):549–553.
20. Leibrock J, Lottspeich F, Hohn A, et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature. 1989;341(6238): 149–152.
21. Pattarawarapan M, Burgess K. Molecular basis of neurotrophin-receptor interactions. J Med Chem. 2003;46(25):5277–5291.
22. Robinson RC, Radziejewski C, Spraggon G, et al. The structures of the neurotrophin 4 homodimer and the brain-derived neurotrophic factor/ neurotrophin 4 heterodimer reveal a common Trk-binding site. Protein Sci. 1999;8(12):2589–2597.
23. Robinson RC, Radziejewski C, Stuart DI, Jones EY. Structure of the brain-derived neurotrophic factor/neurotrophin 3 heterodimer. Biochemistry. 1995;34(13):4139–4146.
24. Maisonpierre PC, Le Beau MM, Espinosa R 3rd, et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics. 1991;10(3):558–568.
25. Hanson IM, Seawright A, van Heyningen V. The human BDNF gene maps between FSHB and HVBS1 at the boundary of 11p13-p14. Genomics. 1992;13(4):1331–1333.
26. Lommatzsch M, Braun A, Mannsfeldt A, et al. Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions. Am J Pathol. 1999;155(4):1183–1193.
27. Garces MF, Sanchez E, Torres-Sierra AL, et al. Brain-derived neu-rotrophic factor is expressed in rat and human placenta and its serum levels are similarly regulated throughout pregnancy in both species. Clin Endocrinol. 2014;81(1):141–151.
28. Lessmann V, Gottmann K, Malcangio M. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol. 2003;69(5):341–374.
29. Negro A, Tavella A, Grandi C, Skaper SD. Production and characterization of recombinant rat brain-derived neurotrophic factor and neurotrophin-3 from insect cells. J Neurochem. 1994;62(2):471–478.
30. Seidah NG, Benjannet S, Pareek S, Chretien M, Murphy RA. Cellular processing of the neurotrophin precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett. 1996;379(3):247–250.
31. Gray K, Ellis V. Activation of pro-BDNF by the pericellular serine protease plasmin. FEBS Lett. 2008;582(6):907–910.
32. Teng HK, Teng KK, Lee R, et al. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. J Neurosci. 2005;25(22):5455–5463.
33. Yang M, Lim Y, Li X, Zhong JH, Zhou XF. Precursor of brain-derived neu-rotrophic factor (proBDNF) forms a complex with Huntingtin-associated protein-1 (HAP1) and sortilin that modulates proBDNF trafficking, degradation, and processing. J Biol Chem. 2011;286(18):16272–16284.
34. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257–269.
35. Ultsch MH, Wiesmann C, Simmons LC, et al. Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC. J Mol Biol. 1999;290(1):149–159.
36. Naylor RL, Robertson AG, Allen SJ, et al. A discrete domain of the human TrkB receptor defnes the binding sites for BDNF and NT-4. Biochem Biophys Res Commun. 2002;291(3):501–507.
37. Massa SM, Yang T, Xie Y, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest. 2010;120(5):1774–1785.
38. Middlemas DS, Lindberg RA, Hunter T. Trk B, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol. 1991;11(1):143–153.
39. Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol. 1994;25(11):1386–1403.
40. Wong J, Rothmond DA, Webster MJ, Weickert CS. Increases in two truncated TrkB isoforms in the prefrontal cortex of people with schizophrenia. Schizophr Bull. 2013;39(1):130–140.
41. Arevalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci. 2006;63(13):1523–1537.
42. Biffo S, Offenhauser N, Carter BD, Barde Y-A. Selective binding and internalisation by truncated receptors restrict the availability of BDNF during development. Development. 1995;121(8):2461–2470.
43. Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci. 1996;16(10):3123–3129.
44. Gruss HJ, Dower SK. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther. 1995;1(2):75–105.
45. Frade JM, Barde YA. Nerve growth factor: two receptors, multiple functions. Bioessays. 1998;20(2):137–145.
46. Tomellini E, Lagadec C, Polakowska R, Le Bourhis X. Role of p75 neurotrophin receptor in stem cell biology: more than just a marker. Cell Mol Life Sci. 2014;71(13):2467–2481.
47. Barker PA. p75NTR is positively promiscuous: novel partners and new insights. Neuron. 2004;42(4):529–533.
48. Skeldal S, Matusica D, Nykjaer A, Coulson EJ. Proteolytic processing of the p75 neurotrophin receptor: a prerequisite for signalling?: Neuronal life, growth and death signalling are crucially regulated by intra-mem-brane proteolysis and trafficking of p75(NTR). Bioessays. 2011;33(8): 614–625.
49. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV. High-affnity NGF binding requires coexpression of the trk proto-oncogene and the low-affnity NGF receptor. Nature. 1991;350(6320): 678–683.
50. Nykjaer A, Lee R, Teng KK, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature. 2004;427(6977):843–848.
51. Jacobsen L, Madsen P, Jacobsen C, Nielsen MS, Gliemann J, Petersen CM. Activation and functional characterization of the mosaic receptor SorLA/LR11. J Biol Chem. 2001;276(25):22788–22796.
52. Atwal JK, Massie B, Miller FD, Kaplan DR. The TrkB-Shc site signals neuronal survival and local axon growth via MEK and P13-kinase. Neuron. 2000;27(2):265–277.
53. Cowansage KK, LeDoux JE, Monfls M-H. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr Mol Pharmacol. 2010;3(1):12–29.
54. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nature Reviews Neuroscience. 2003; 4(4):299–309.
55. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545–1564.
56. Amaral MD, Pozzo-Miller L. TRPC3 channels are necessary for brain-derived neurotrophic factor to activate a nonselective cationic current and to induce dendritic spine formation. J Neurosci. 2007;27(19): 5179–5189.
57. Blanquet PR, Mariani J, Derer P. A calcium/calmodulin kinase pathway connects brain-derived neurotrophic factor to the cyclic AMP-responsive transcription factor in the rat hippocampus. Neuroscience. 2003;118(2):477–490.
58. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev. 2006;58(1):115–134.
59. Zheng WH, Quirion R. Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. J Neu-rochem. 2004;89(4):844–852.
60. Perez-Navarro E, Gavalda N, Gratacos E, Alberch J. Brain-derived neurotrophic factor prevents changes in Bcl-2 family members and caspase-3 activation induced by excitotoxicity in the striatum. J Neu-rochem. 2005;92(3):678–691.
61. Takei N, Inamura N, Kawamura M, et al. Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci. 2004;24(44):9760–9769.
62. Slipczuk L, Bekinschtein P, Katche C, Cammarota M, Izquierdo I, Medina JH. BDNF activates mTOR to regulate GluR1 expression required for memory formation. PloS One. 2009;4(6):e6007.
63. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H. BDNF function and intracellular signaling in neurons. Histol Histo-pathol. 2010;25(2):237–258.
64. Hao Y, Creson T, Zhang L, et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci. 2004;24(29):6590–6599.
65. Bibel M, Hoppe E, Barde YA. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J. 1999; 18(3):616–622.
66. Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci. 2004;7(3): 221–228.
67. Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin Sci. 2006;110(2):167–173.
68. Zotti T, Vito P, Stilo R. The seventh ring: exploring TRAF7 functions. J Cell Physiol. 2012;227(3):1280–1284.
69. Kanamoto T, Mota M, Takeda K, et al. Role of apoptosis signal-regulating kinase in regulation of the c-Jun N-terminal kinase pathway and apoptosis in sympathetic neurons. Mol Cell Biol. 2000;20(1): 196–204.
70. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene. 2008;27(48):6245–6251.
71. MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A. 2002;99(14): 9492–9497.
72. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80(2):293–299.
73. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev. 2006;70(4): 1061–1095.
74. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol. 2002;3(3):221–227.
75. Gentry JJ, Barker PA, Carter BD. The p75 neurotrophin receptor: multiple interactors and numerous functions. Prog Brain Res. 2004;146: 25–39.
76. Dobrowsky RT, Werner MH, Castellino AM, Chao MV, Hannun YA. Activation of the sphingomyelin cycle through the low-affnity neu-rotrophin receptor. Science. 1994;265(5178):1596–1599.
77. Lewin GR, Carter BD. Neurotrophic Factors – Handbook of Experimental Pharmacology, vol. 220. Berlin, Heidelberg: Springer-Verlag; 2014:129.
78. Jonas JB, Bourne RR, White RA, et al. Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis. Am J Ophthalmol. 2014;158(4):808–815.
79. Bourne RR, Jonas JB, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990–2010. Br J Ophthalmol. 2014;98(5):629–638.
80. Nickells RW, Zack DJ. Apoptosis in ocular disease: a molecular overview. Ophthalmic Genet. 1996;17(4):145–165.
81. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res. 1999; 18(1):39–57.
82. Bernstein SL, Guo Y, Kelman SE, Flower RW, Johnson MA. Functional and cellular responses in a novel rodent model of anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci. 2003;44(10): 4153–4162.
83. Medeiros NE, Curcio CA. Preservation of ganglion cell layer neurons in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42(3):795–803.
84. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol. 2008;586(Pt 18):4401–4408.
85. Shindler KS, Guan Y, Ventura E, Bennett J, Rostami A. Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult Scler. 2006;12(5):526–532.
86. Johnson JE, Barde YA, Schwab M, Thoenen H. Brain-derived neu-rotrophic factor supports the survival of cultured rat retinal ganglion cells. J Neurosci. 1986;6(10):3031–3038.
87. Di Polo A, Cheng L, Bray GM, Aguayo AJ. Colocalization of TrkB and brain-derived neurotrophic factor proteins in green-red–sensitive cone outer segments. Invest Ophthalmol Vis Sci. 2000;41(12): 4014–4021.
88. Cellerino A, Kohler K. Brain-derived neurotrophic factor/neurotro-phin-4 receptor TrkB is localized on ganglion cells and dopaminergic amacrine cells in the vertebrate retina. J Comp Neurol. 1997;386(1): 149–160.
89. Rohrer B, Korenbrot JI, LaVail MM, Reichardt LF, Xu B. Role of neurotrophin receptor TrkB in the maturation of rod photoreceptors and establishment of synaptic transmission to the inner retina. J Neurosci. 1999;19(20):8919–8930.
90. Jelsma TN, Friedman HH, Berkelaar M, Bray GM, Aguayo AJ. Different forms of the neurotrophin receptor trkB mRNA predominate in rat retina and optic nerve. J Neurobiol. 1993;24(9):1207–1214.
91. Steuer H, Jaworski A, Elger B, et al. Functional characterization and comparison of the outer blood-retina barrier and the blood–brain barrier. Invest Ophthalmol Vis Sci. 2005;46(3):1047–1053.
92. Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo J. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci U S A. 1994;91(5): 1632–1636.
93. Klocker N, Kermer P, Weishaupt JH, Labes M, Ankerhold R, Bahr M. Brain-derived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3′-kinase/protein kinase B signaling. J Neurosci. 2000;20(18):6962–6967.
94. Nakazawa T, Tamai M, Mori N. Brain-derived neurotrophic factor prevents axotomized retinal ganglion cell death through MAPK and PI3K signaling pathways. Invest Ophthalmol Vis Sci. 2002;43(10):3319–3326.
95. Weibel D, Cadelli D, Schwab ME. Regeneration of lesioned rat optic nerve fibers is improved after neutralization of myelin-associated neurite growth inhibitors. Brain Res. 1994;642(1–2):259–266.
96. Weibel D, Kreutzberg GW, Schwab ME. Brain-derived neurotrophic factor (BDNF) prevents lesion-induced axonal die-back in young rat optic nerve. Brain Res. 1995;679(2):249–254.
97. Chen H, Weber AJ. BDNF enhances retinal ganglion cell survival in cats with optic nerve damage. Invest Ophthalmol Vis Sci. 2001;42(5): 966–974.
98. Galindo-Romero C, Valiente-Soriano FJ, Jimenez-Lopez M, et al. Effect of brain-derived neurotrophic factor on mouse axotomized retinal ganglion cells and phagocytic microglia. Invest Ophthalmol Vis Sci. 2013;54(2):974–985.
99. Zhang CW, Lu Q, Yo u SW, et al. CNTF and BDNF have similar effects on retinal ganglion cell survival but differential effects on nitric oxide synthase expression soon after optic nerve injury. Invest Ophthalmol Vis Sci. 2005;46(4):1497–1503.
100. LaVail MM, Gorrin GM. Protection from light damage by ocular pigmentation: analysis using experimental chimeras and translocation mice. Exp Eye Res. 1987;44(6):877–889.
101. Ko ML, Hu DN, Ritch R, Sharma SC. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41(10): 2967–2971.
102. Ikeda K, Tanihara H, Honda Y, Tatsuno T, Noguchi H, Nakayama C. BDNF attenuates retinal cell death caused by chemically induced hypoxia in rats. Invest Ophthalmol Vis Sci. 1999;40(9):2130–2140.
103. Kido N, Tanihara H, Honjo M, et al. Neuroprotective effects of brain-derived neurotrophic factor in eyes with NMDA-induced neuronal death. Brain Res. 2000;884(1–2):59–67.
104. Tomita M, Adachi Y, Yamada H, et al. Bone marrow-derived stem cells can differentiate into retinal cells in injured rat retina. Stem Cells. 2002;20(4):279–283.
105. Lawrence JM, Keegan DJ, Muir EM, et al. Transplantation of Schwann cell line clones secreting GDNF or BDNF into the retinas of dystrophic Royal College of Surgeons rats. Invest Ophthalmol Vis Sci. 2004;45(1): 267–274.
106. Cellerino A, Pinzon-Duarte G, Carroll P, Kohler K. Brain-derived neurotrophic factor modulates the development of the dop-aminergic network in the rodent retina. J Neurosci. 1998;18(9): 3351–3362.
107. Mey J, Thanos S. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res. 1993;602(2):304–317.
108. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998;39(3):592–602.
109. Chen H, Weber AJ. Brain-derived neurotrophic factor reduces TrkB protein and mRNA in the normal retina and following optic nerve crush in adult rats. Brain Res. 2004;1011(1):99–106.
110. Marticorena J, Romano V, Gomez-Ulla F. Sterile endophthal-mitis after intravitreal injections. Mediators Infamm. 2012;2012: 928123.
111. Suzuki T, Ooto S, Akagi T, et al. Effects of prolonged delivery of brain-derived neurotrophic factor on the fate of neural stem cells transplanted into the developing rat retina. Biochem Biophys Res Commun. 2003;309(4):843–847.
112. Fu QL, Li X, Yip HK, et al. Combined effect of brain-derived neu-rotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience. 2009;162(2): 375–382.
113. Koeberle PD, Ball AK. Neurturin enhances the survival of axotomized retinal ganglion cells in vivo: combined effects with glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor. Neuroscience. 2002;110(3):555–567.
114. Watanabe M, Tokita Y, Kato M, Fukuda Y. Intravitreal injections of neurotrophic factors and forskolin enhance survival and axonal regeneration of axotomized beta ganglion cells in cat retina. Neuroscience. 2003;116(3):733–742.
115. Tropea D, Caleo M, Maffei L. Synergistic effects of brain-derived neurotrophic factor and chondroitinase ABC on retinal fiber sprouting after denervation of the superior colliculus in adult rats. J Neurosci. 2003;23(18):7034–7044.
116. Klocker N, Cellerino A, Bahr M. Free radical scavenging and inhibition of nitric oxide synthase potentiates the neurotrophic effects of brain-derived neurotrophic factor on axotomized retinal ganglion cells in vivo. J Neurosci. 1998;18(3):1038–1046.
117. Weber AJ, Viswanathan S, Ramanathan C, Harman CD. Combined application of BDNF to the eye and brain enhances ganglion cell survival and function in the cat after optic nerve injury. Invest Ophthalmol Vis Sci. 2010;51(1):327–334.
118. Guy J, Qi X, Muzyczka N, Hauswirth WW. Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol. 1999;117(7):929–937.
119. Xiao X, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol. 1997;144(1):113–124.
120. Bennett J, Wilson J, Sun D, Forbes B, Maguire A. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci. 1994;35(5):2535–2542.
121. Di Polo A, Aigner LJ, Dunn RJ, Bray GM, Aguayo AJ. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Müller cells temporarily rescues injured retinal ganglion cells. Proc Natl Acad Sci U S A. 1998;95(7):3978–3983.
122. Gauthier R, Joly S, Pernet V, Lachapelle P, Di Polo A. Brain-derived neurotrophic factor gene delivery to muller glia preserves structure and function of light-damaged photoreceptors. Invest Ophthalmol Vis Sci. 2005;46(9):3383–3392.
123. Schuettauf F, Vorwerk C, Naskar R, et al. Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity. Curr Eye Res. 2004;29(6):379–386.
124. Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44(10): 4357–4365.
125. Mo X, Yokoyama A, Oshitari T, et al. Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in adult rats. Invest Ophthalmol Vis Sci. 2002;43(7):2401–2405.
126. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996;70(5): 3227–3234.
127. Ren R, Li Y, Liu Z, Liu K, He S. Long-term rescue of rat retinal ganglion cells and visual function by AAV-mediated BDNF expression after acute elevation of intraocular pressure. Invest Ophthalmol Vis Sci. 2012;53(2):1003–1011.
128. Zhang Y, Wang W. Effects of bone marrow mesenchymal stem cell transplantation on light-damaged retina. Invest Ophthalmol Vis Sci. 2010;51(7):3742–3748.
129. Park HY, Kim JH, Sun Kim H, Park CK. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina. Brain Res. 2012;1469:10–23.
130. Zhou X-M, Yuan H-P, Wu D-L, et al. Study of brain-derived neu-rotrophic factor gene transgenic neural stem cells in the rat retina. Chin Med J (Engl). 2009;122(14):1642.
131. Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies. Gene Ther. 2008;15(10):716–729.
132. Abe T, Wakusawa R, Seto H, Asai N, Saito T, Nishida K. Topical doxycycline can induce expression of BDNF in transduced retinal pigment epithelial cells transplanted into the subretinal space. Invest Ophthalmol Vis Sci. 2008;49(8):3631–3639.
133. Goldenberg-Cohen N, Avraham-Lubin BC, Sadikov T, Askenasy N. Effect of coadministration of neuronal growth factors on neuroglial differentiation of bone marrow-derived stem cells in the ischemic retina. Invest Ophthalmol Vis Sci. 2014;55(1):502–512.
134. Johnson TV, Bull ND, Martin KR. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res. 2011;93(2):196–203.
135. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010; 51(11):5403–5420.
136. Kaur IP, Kakkar S. Nanotherapy for posterior eye diseases. J Control Release. 2014;193:100–112.
137. Sakai T, Kuno N, Takamatsu F, et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in royal college of surgeons rats. Invest Ophthalmol Vis Sci. 2007;48(7):3381–3387.
138. WHO. Deafness and Hearing Loss. Switzerland, Geneva: WHO; 2014. Available from: http://www.who.int/mediacentre/factsheets/fs300/en/. Accessed October 2, 2014.
139. Fellinger J, Holzinger D, Gerich J, Goldberg D. Mental distress and quality of life in the hard of hearing. Acta Psychiatr Scand. 2007; 115(3):243–245.
140. Wilson BS, Dorman MF. Cochlear implants: a remarkable past and a brilliant future. Hear Res. 2008;242(1–2):3–21.
141. Fritzsch B, Pirvola U, Ylikoski J. Making and breaking the innerva-tion of the ear: neurotrophic support during ear development and its clinical implications. Cell Tissue Res. 1999;295(3):369–382.
142. Ernfors P, Lee KF, Jaenisch R. Mice lacking brain-derived neu-rotrophic factor develop with sensory deficits. Nature. 1994; 368(6467):147–150.
143. Fukui H, Wong HT, Beyer LA, et al. BDNF gene therapy induces auditory nerve survival and fiber sprouting in deaf Pou4f3 mutant mice. Sci Rep. 2012;2:838.
144. Juhn SK, Haugen J, Steven L. Some chemical parameters of serum, cerebrospinal fuid, perilymph, and aqueous humor of the chinchilla. Lab Anim Sci. 1974;24(4):691–695.
145. Staecker H, Brough DE, Praetorius M, Baker K. Drug delivery to the inner ear using gene therapy. Otolaryngol Clin North Am. 2004;37(5): 1091–1108.
146. Budenz CL, Pfngst BE, Raphael Y. The use of neurotrophin therapy in the inner ear to augment cochlear implantation outcomes. Anat Rec (Hoboken). 2012;295(11):1896–1908.
147. Johnsson LG, Hawkins JE Jr. Strial atrophy in clinical and experimental deafness. Laryngoscope. 1972;82(7):1105–1125.
148. Meen E, Blakley B, Quddusi T. Brain-derived nerve growth factor in the treatment of sensorineural hearing loss. Laryngoscope. 2009;119(8): 1590–1593.
149. Shoji F, Miller AL, Mitchell A, Yamasoba T, Altschuler RA, Miller JM. Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss. Hear Res. 2000;146(1–2):134–142.
150. Hendricks JL, Chikar JA, Crumling MA, Raphael Y, Martin DC. Localized cell and drug delivery for auditory prostheses. Hear Res. 2008;242(1–2):117–131.
151. Radeloff A, Smolders J W. Brain-derived neurotrophic factor treatment does not improve functional recovery after hair cell regeneration in the pigeon. Acta Otolaryngol. 2006;126(5):452–459.
152. Ruan RS, Leong SK, Mark I, Yeoh KH. Effects of BDNF and NT-3 on hair cell survival in guinea pig cochlea damaged by kanamycin treatment. Neuroreport. 1999;10(10):2067–2071.
153. Miller JM, Chi DH, O’Keeffe LJ, Kruszka P, Raphael Y, Altschuler RA. Neurotrophins can enhance spiral ganglion cell survival after inner hair cell loss. Int J Dev Neurosci. 1997;15(4–5):631–643.
154. Meen E, Blakley B, Quddusi T. Does intracochlear brain-derived nerve growth factor improve auditory brainstem click thresholds in sensorineural hearing loss? J Otolaryngol Head Neck Surg. 2010;39(3):232–235.
155. Gillespie LN, Clark GM, Bartlett PF, Marzella PL. BDNF-induced survival of auditory neurons in vivo: cessation of treatment leads to accelerated loss of survival effects. J Neurosci Res. 2003;71(6):785–790.
156. Montero CN, Hefti F. Rescue of lesioned septal cholinergic neurons by nerve growth factor: specificity and requirement for chronic treatment. J Neurosci. 1988;8(8):2986–2999.
157. Leake PA, Hradek GT, Rebscher SJ, Snyder RL. Chronic intracochlear electrical stimulation induces selective survival of spiral ganglion neurons in neonatally deafened cats. Hear Res. 1991;54(2):251–271.
158. Mitchell A, Miller JM, Finger PA, Heller JW, Raphael Y, Altschuler RA. Effects of chronic high-rate electrical stimulation on the cochlea and eighth nerve in the deafened guinea pig. Hear Res. 1997;105(1–2): 30–43.
159. Shepherd RK, Matsushima J, Martin RL, Clark GM. Cochlear pathology following chronic electrical stimulation of the auditory nerve: II. Deafened kittens. Hear Res. 1994;81(1–2):150–166.
160. Leake PA, Stakhovskaya O, Hetherington A, Rebscher SJ, Bonham B. Effects of brain-derived neurotrophic factor (BDNF) and electrical stimulation on survival and function of cochlear spiral ganglion neurons in deafened, developing cats. J Assoc Res Otolaryngol. 2013;14(2): 187–211.
161. Song BN, Li YX, Han DM. Delayed electrical stimulation and BDNF application following induced deafness in rats. Acta Otolaryngol. 2009;129(2):142–154.
162. Landry TG, Wise AK, Fallon JB, Shepherd RK. Spiral ganglion neuron survival and function in the deafened cochlea following chronic neurotrophic treatment. Hear Res. 2011;282(1–2):303–313.
163. Shepherd RK, Coco A, Epp SB. Neurotrophins and electrical stimulation for protection and repair of spiral ganglion neurons following sensorineural hearing loss. Hear Res. 2008;242(1–2):100–109.
164. Maruyama J, Miller JM, Ulfendahl M. Glial cell line-derived neu-rotrophic factor and antioxidants preserve the electrical responsiveness of the spiral ganglion neurons after experimentally induced deafness. Neurobiol Dis. 2008;29(1):14–21.
165. Glueckert R, Bitsche M, Miller JM, et al. Deafferentation-associated changes in afferent and efferent processes in the guinea pig cochlea and afferent regeneration with chronic intrascalar brain-derived neu-rotrophic factor and acidic fibroblast growth factor. J Comp Neurol. 2008;507(4):1602–1621.
166. Hartnick CJ, Staecker H, Malgrange B, et al. Neurotrophic effects of BDNF and CNTF, alone and in combination, on postnatal day 5 rat acoustic ganglion neurons. J Neurobiol. 1996;30(2):246–254.
167. Pettingill LN, Richardson RT, Wise AK, O’Leary SJ, Shepherd RK. Neurotrophic factors and neural prostheses: potential clinical applications based upon fndings in the auditory system. IEEE Trans Biomed Eng. 2007;54(6 Pt 1):1138–1148.
168. Sacheli R, Delacroix L, Vandenackerveken P, Nguyen L, Malgrange B. Gene transfer in inner ear cells: a challenging race. Gene Ther. 2013; 20(3):237–247.
169. Wise AK, Hume CR, Flynn BO, et al. Effects of localized neurotrophin gene expression on spiral ganglion neuron resprouting in the deafened cochlea. Mol Ther. 2010;18(6):1111–1122.
170. Staecker H, Gabaizadeh R, Federoff H, Van De Water TR. Brain-derived neurotrophic factor gene therapy prevents spiral ganglion degeneration after hair cell loss. Otolaryngol Head Neck Surg. 1998;119(1):7–13.
171. Rejali D, Lee VA, Abrashkin KA, Humayun N, Swiderski DL, Raphael Y. Cochlear implants and ex vivo BDNF gene therapy protect spiral ganglion neurons. Hear Res. 2007;228(1–2):180–187.
172. Nakaizumi T, Kawamoto K, Minoda R, Raphael Y. Adenovirus-me-diated expression of brain-derived neurotrophic factor protects spiral ganglion neurons from ototoxic damage. Audiol Neurootol. 2004;9(3): 135–143.
173. Chikar JA, Colesa DJ, Swiderski DL, Di Polo A, Raphael Y, Pfngst BE. Over-expression of BDNF by adenovirus with concurrent electrical stimulation improves cochlear implant thresholds and survival of auditory neurons. Hear Res. 2008;245(1–2):24–34.
174. Holt JR, Johns DC, Wang S, et al. Functional expression of exogenous proteins in mammalian sensory hair cells infected with adenoviral vectors. J Neurophysiol. 1999;81(4):1881–1888.
175. Stone IM, Lurie DI, Kelley MW, Poulsen DJ. Adeno-associated virus-mediated gene transfer to hair cells and support cells of the murine cochlea. Mol Ther. 2005;11(6):843–848.
176. Duan ML, Bordet T, Mezzina M, Kahn A, Ulfendahl M. Adenoviral and adeno-associated viral vector mediated gene transfer in the guinea pig cochlea. Neuroreport. 2002;13(10):1295–1299.
177. Shibata SB, Cortez SR, Beyer LA, et al. Transgenic BDNF induces nerve fiber regrowth into the auditory epithelium in deaf cochleae. Exp Neurol. 2010;223(2):464–472.
178. Ito J, Endo T, Nakagawa T, Kita T, Kim TS, Iguchi F. A new method for drug application to the inner ear. ORL J Otorhinolaryngol Relat Spec. 2005;67(5):272–275.
179. Havenith S, Versnel H, Agterberg MJ, et al. Spiral ganglion cell survival after round window membrane application of brain-derived neurotrophic factor using gelfoam as carrier. Hear Res. 2011; 272(1–2):168–177.
180. Sakamoto T, Nakagawa T, Horie RT, et al. Inner ear drug delivery system from the clinical point of view. Acta Otolaryngol Suppl. 2010; (563):101–104.
181. Gillespie LN, Shepherd RK. Clinical application of neurotrophic factors: the potential for primary auditory neuron protection. Eur J Neurosci. 2005;22(9):2123–2133.
182. Pettingill LN, Wise AK, Geaney MS, Shepherd RK. Enhanced auditory neuron survival following cell-based BDNF treatment in the deaf guinea pig. PloS One. 2011;6(4):e18733.
183. Di Toro R, Betti V, Spampinato S. Biocompatibility and integrin-mediated adhesion of human osteoblasts to poly (DL-lactide-co-glycolide) copolymers. Eur J Pharm Sci. 2004;21(2):161–169.
184. Tamura T, Kita T, Nakagawa T, et al. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope. 2005;115(11):2000–2005.
185. Ge X, Jackson RL, Liu J, et al. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol Head Neck Surg. 2007;137(4): 619–623.
186. Arlinger S. Negative consequences of uncorrected hearing loss – a review. Int J Audiol. 2003;42(Suppl 2):2S17–2S20.
187. Horowitz A. The prevalence and consequences of vision impairment in later life. Top Geriatr Rehabil. 2004;20(3):185–195.
188. Kirk EC, Gosselin-Ildari AD. Cochlear labyrinth volume and hearing abilities in primates. Anat Rec (Hoboken). 2009;292(6):765–776.
189. Frank L, Wiegand SJ, Siuciak JA, Lindsay RM, Rudge JS. Effects of BDNF infusion on the regulation of TrkB protein and message in adult rat brain. Exp Neurol. 1997;145(1):62–70.
190. Scharfman HE, Goodman JH, Sollas AL, Croll SD. Spontaneous limbic seizures after intrahippocampal infusion of brain-derived neurotrophic factor. Exp Neurol. 2002;174(2):201–214.
191. Binder DK, Croll SD, Gall CM, Scharfman HE. BDNF and epilepsy: too much of a good thing? Trends Neurosci. 2001;24(1):47–53.
192. Shinohara T, Bredberg G, Ulfendahl M, et al. Neurotrophic factor intervention restores auditory function in deafened animals. Proc Natl Acad Sci U S A. 2002;99(3):1657–1660.
193. Shepherd RK, Coco A, Epp SB, Crook JM. Chronic depolarization enhances the trophic effects of brain-derived neurotrophic factor in rescuing auditory neurons following a sensorineural hearing loss. J Comp Neurol. 2005;486(2):145–158.
194. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70(11):8098–8108.
195. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006;103(10):3896–3901.
196. Adunka O, Unkelbach MH, Mack M, Hambek M, Gstoettner W, Kiefer J. Cochlear implantation via the round window membrane minimizes trauma to cochlear structures: a histologically controlled insertion study. Acta Otolaryngol. 2004;124(7):807–812.
197. Unoki K, LaVail MM. Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic fibroblast growth factor. Invest Ophthalmol Vis Sci. 1994;35(3):907–915.
198. Sawai H, Clarke DB, Kittlerova P, Bray GM, Aguayo AJ. Brain-derived neurotrophic factor and neurotrophin-4/5 stimulate growth of axonal branches from regenerating retinal ganglion cells. J Neurosci. 1996;16(12):3887–3894.
199. Peinado-Ramon P, Salvador M, Villegas-Perez MP, Vidal-Sanz M. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study. Invest Ophthalmol Vis Sci. 1996;37(4):489–500.
200. Cellerino A, Arango-Gonzalez BA, Kohler K. Effects of brain-derived neurotrophic factor on the development of NADPH-diaphorase/nitric oxide synthase-positive amacrine cells in the rodent retina. Eur J Neurosci. 1999;11(8):2824–2834.
201. Kurokawa T, Katai N, Shibuki H, et al. BDNF diminishes caspase-2 but not c-Jun immunoreactivity of neurons in retinal ganglion cell layer after transient ischemia. Invest Ophthalmol Vis Sci. 1999;40(12):3006–3011.
202. Chen H, Weber AJ. Expression of glial fibrillary acidic protein and glutamine synthetase by Müller cells after optic nerve damage and intravitreal application of brain-derived neurotrophic factor. Glia. 2002;38(2):115–125.
203. Ota T, Hara H, Miyawaki N. Brain-derived neurotrophic factor inhibits changes in soma-size of retinal ganglion cells following optic nerve axotomy in rats. J Ocul Pharmacol Ther. 2002;18(3):241–249.
204. Krueger-Naug A, Emsley J, Myers T, Currie R, Clarke D. Administration of brain-derived neurotrophic factor suppresses the expression of heat shock protein 27 in rat retinal ganglion cells following axotomy. Neuroscience. 2003;116(1):49–58.
205. Lee EJ, Song MC, Kim HJ, et al. Brain-derived neurotrophic factor modulates the dopaminergic network in the rat retina after axotomy. Cell Tissue Res. 2005;322(2):191–199.
206. Chen R, Yin XB, Peng CX, Li GL. Effect of brain-derived neurotrophic factor on c-jun expression in the rd mouse retina. Int J Ophthalmol. 2012;5(3):266–271.
207. Yan Q, Wang J, Matheson CR, Urich JL. Glial cell line-derived neu-rotrophic factor (GDNF) promotes the survival of axotomized retinal ganglion cells in adult rats: comparison to and combination with brain-derived neurotrophic factor (BDNF). J Neurobiol. 1999;38(3): 382–390.
208. Weber AJ, Harman CD. BDNF treatment and extended recovery from optic nerve trauma in the cat. Invest Ophthalmol Vis Sci. 2013;54(10): 6594–6604.
209. Wang JM, Sun NX, Hui N, Fan YZ, Feng HX, Zhao SP. [Effects of rAAV-mediated rhBDNF gene transfection on BDNF gene expression in the retina of a rabbit model of acute high intraocular pressure]. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(11):2201–2204. Chinese.
210. Wan C, Liu NN, Liu LM, Cai N, Chen L. Effect of adenovirus-mediated brain derived neurotrophic factor in early retinal neuropathy of diabetes in rats. Int J Ophthalmol. 2010;3(2):145–148.
211. McGuinness SL, Shepherd RK. Exogenous BDNF rescues rat spiral ganglion neurons in vivo. Otol Neurotol. 2005;26(5):1064–1072.
212. Agterberg MJ, Versnel H, de Groot JC, Smoorenburg GF, Albers FW, Klis SF. Morphological changes in spiral ganglion cells after intra-cochlear application of brain-derived neurotrophic factor in deafened guinea pigs. Hear Res. 2008;244(1–2):25–34.
213. Song BN, Li YX, Han DM. Effects of delayed brain-derived neu-rotrophic factor application on cochlear pathology and auditory physiology in rats. Chin Med J. 2008;121(13):1189–1196.
214. Agterberg MJ, Versnel H, van Dijk LM, de Groot JC, Klis SF. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. J Assoc Res Otolaryngol. 2009;10(3):355–367.
215. Sly DJ, Hampson AJ, Minter RL, et al. Brain-derived neurotrophic factor modulates auditory function in the hearing cochlea. J Assoc Res Otolaryngol. 2012;13(1):1–16.
216. Leake PA, Hradek GT, Hetherington AM, Stakhovskaya O. Brain-derived neurotrophic factor promotes cochlear spiral ganglion cell survival and function in deafened, developing cats. J Comp Neurol. 2011;519(8):1526–1545.
217. Waaijer L, Klis SF, Ramekers D, Van Deurzen MH, Hendriksen FG, Grolman W. The peripheral processes of spiral ganglion cells after intracochlear application of brain-derived neurotrophic factor in deafened guinea pigs. Otol Neurotol. 2013;34(3):570–578.
218. van Loon MC, Ramekers D, Agterberg MJ, et al. Spiral ganglion cell morphology in guinea pigs after deafening and neurotrophic treatment. Hear Res. 2013;298:17–26.
219. Yamagata T, Miller JM, Ulfendahl M, et al. Delayed neurotrophic treatment preserves nerve survival and electrophysiological responsiveness in neomycin-deafened guinea pigs. J Neurosci Res. 2004;78(1):75–86.
220. Wise AK, Richardson R, Hardman J, Clark G, O’Leary S. Resprout-ing and survival of guinea pig cochlear neurons in response to the administration of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3. J Comp Neurol. 2005;487(2):147–165.
221. Miller JM, Le Prell CG, Prieskorn DM, Wys NL, Altschuler RA. Delayed neurotrophin treatment following deafness rescues spiral ganglion cells from death and promotes regrowth of auditory nerve peripheral processes: effects of brain-derived neurotrophic factor and fibroblast growth factor. J Neurosci Res. 2007;85(9):1959–1969.
222. Lalwani AK, Han JJ, Castelein CM, Carvalho GJ, Mhatre AN. In vitro and in vivo assessment of the ability of adeno-associated virus–brain-derived neurotrophic factor to enhance spiral ganglion cell survival following ototoxic insult. Laryngoscope. 2002;112(8): 1325–1334.
223. Li L, Shui QX, Li X. Neuroprotective effects of brain-derived neu-rotrophic factor (BDNF) on hearing in experimental pneumococcal meningitis. J Child Neurol. 2005;20(1):51–56.